Understanding Fc Receptor Involvement in Inflammatory Diseases: From Mechanisms to New Therapeutic Tools

Sanané Ben Mkaddem, Marc Benhamou and Renato C. Monteiro

1 INSERM U1149, Centre de Recherche sur l’Inflammation, Paris, France, 2 CNRS ERL8252, Paris, France, 3 Faculté de Médecine, Université Paris Diderot, Sorbonne Paris Cité, Site Xavier Bichat, Paris, France, 4 Inflamex Laboratory of Excellence, Paris, France, 5 Service d’Immunologie, DHU Fire, Hôpital Bichat-Claude Bernard, Assistance Publique de Paris, Paris, France

Fc receptors (FcRs) belong to the ITAM-associated receptor family. FcRs control the humoral and innate immunity which are essential for appropriate responses to infections and prevention of chronic inflammation or auto-immune diseases. Following their crosslinking by immune complexes, FcRs play various roles such as modulation of the immune response by released cytokines or of phagocytosis. Here, we review FcR involvement in pathologies leading notably to altered intracellular signaling with functionally relevant consequences to the host, and targeting of Fc receptors as therapeutic approaches. Special emphasis will be given to some FcRs, such as the FcαRI, the FcγRIIA and the FcγRIIIA, which behave like the ancient god Janus depending on the ITAM motif to inhibit or activate immune responses depending on their targeting by monomeric/dimeric immunoglobulins or by immune complexes. This ITAM duality has been recently defined as inhibitory or activating ITAM (ITAMI or ITAMa) which are controlled by Src family kinases. Involvement of various ITAM-bearing FcRs observed during infectious or autoimmune diseases is associated with allelic variants, changes in ligand binding ability responsible for host defense perturbation. During auto-immune diseases such as rheumatoid arthritis, lupus or immune thrombocytopenia, the autoantibodies and immune complexes lead to inflammation through FcR aggregation. We will discuss the role of FcRs in autoimmune diseases, and focus on novel approaches to target FcRs for resolution of antibody-mediated autoimmunity. We will finally also discuss the down-regulation of FcR functionality as a therapeutic approach for autoimmune diseases.

Keywords: immunoglobulins, Fc receptor, antibody treatment, signaling/signaling pathways, inflammatory diseases

FC RECEPTOR MODES OF ACTION

Immunoglobulin Fc receptors (FcRs) are membrane molecules expressed by several hematopoietic cells that recognize the Fc region of several immunoglobulin (Ig) classes and subclasses. We distinguish FcR for IgG (FcγRI/CD64, FcγRII/CD32, and FcγRIII/CD16), IgE (FcεRI), IgA (FcαRI/CD89), IgM (FcγRI), and IgA/IgM (Fcα/μR). Several other receptors expressed on different
cell types also bind Ig molecules: neonatal FcR for IgG (FcRn) on intestinal epithelium, placenta, and endothelium, low affinity FceR (FceRII/CD23) on B cells and macrophages, and polymeric Ig receptor (pIgR) on mucosal epithelium (1–3). The function of antibodies depends on one hand on their ability to recognize antigenic epitopes and, on the other hand, on their dynamic flexibility and their capacity to interact with their cognate FcRs. Engagement of FcRs expressed by leukocytes initiates a number of pro-inflammatory, anti-inflammatory, and immune modulatory functions in the host adaptive immune responses leading to protection but sometimes also to disease.

Several FcRs require the Immunoreceptor Tyrosine-based Activation Motif (ITAM; with the sequence Yxx[L/I]x6–8Yxx[L/I]) present in the cytoplasmic tail of the receptor or of associated subunits (FcγR or FcεRIβ chain) to induce cell signaling. ITAM-mediated functions include phagocytosis, degranulation, antibody-dependent cellular cytotoxicity (ADCC), cytokine, lipid mediator and superoxide production, all of which depend on the cell type and on outside-in signals induced by the ligand. Engagement of the type I FcRs by immune complexes, induces receptor aggregation followed by activation and recruitment of Src family kinases (SFKs), such as Lyn and Fyn (4). The former induces the phosphorylation of the conserved tyrosines in the ITAM motif, followed by activation and recruitment of the tyrosine kinase Syk. This process activates various proteins involved in cell response, such as Phospholipase C gamma 1 (PLCγ), Bruton’s tyrosine kinase (Btk), guanine nucleotide exchange factor Vav and phosphoinositide 3-kinase (PI3K).

The activation of ITAM-bearing immune receptors can be retro-controlled by ITIM-bearing inhibitory FcRs such as the FcγRIIB. The ITIM motif is defined by a single [I/V/L/S]x6–8Yxx[L/V] sequence. However, inhibition of cell activation by this motif requires co-ligation between the inhibitory and heterologous activating receptors by immune complexes promoting the recruitment of inositol phosphatases (SHIP-1 and SHIP-2) (6) (Figure 1, Middle). Another inhibitory mechanism has been recently identified that involves ITAM itself. Indeed, following low avidity ligand interactions, ITAM-bearing FcRs induce a sustained inhibitory signal without co-ligation with heterologous receptors. This mechanism was involved in the maintenance of immune homeostasis (7–14). We named this ITAM-mediated inhibitory signal, ITAMI. It has been shown that several low affinity receptors, such as FcεRI, FcγRIIb and FcγRIllA, can function as such bi-functional receptors to induce either activating or inhibitory signals, a property that can be exploited to reduce the susceptibility to autoimmune and inflammatory diseases (11). Monovalent or divalent targeting of FcRs bearing an ITAM motif induced ITAMI signals that involved activation and recruitment of the Src homology region 2 domain-containing tyrosine phosphatase SHP-1 (Figure 1, Right). It has been demonstrated that other immunoreceptors such as the antigen receptors BCR and TCR can also associate with SHP-1 upon interaction with low avidity ligands (15, 16). Moreover, SHP-1 deficiency in hematopoietic cells favors development of various auto-immunes diseases. For example, the motheaten mice (mev/mev) which express approximately 20% wild type activity of SHP-1, develop severe immune dysregulation and autoantibody production (17).

During ITAMI signaling induced by FcRs, Lyn is essential for the phosphorylation (on tyrosine residue 536) and the activation of SHP-1 (4). It has been reported that Lyn is involved in positive and negative signals induced by antigen receptors (18, 19). Lyn plays an important role in the negative selection of B cells in the bone marrow, since the absence of Lyn was associated with a decreased B cell number in the periphery of mice. In the absence of Lyn, other SFKs, such as Fyn, act as positive regulators of BCR signaling, suggesting a loss of anergy. The opposite roles of Lyn and Fyn were recently demonstrated by in vivo approaches. Lyn deficiency aggravates autoimmune/inflammatory diseases such as nephritis and arthritis, while the absence of Fyn protects against these diseases (4). Additionally, we showed that activation of leukocytes in lupus nephritis patients was associated with Fyn-activated signature, suggesting that the balance between Lyn and Fyn is dysregulated during diseases.

Another FcR that play an essential role in the transcytosis by epithelial cells of dimeric IgA, but also pentameric IgM (notably during IgA deficiencies), is called the polymeric immunoglobulin receptor (pIgR). The pIgR is internalized with its ligands by endocytosis and transcytosed from the basolateral membrane into apical side of the epithelial cell (20). The central role of this receptor is to generate secretory IgA (formed of IgA dimers linked to the extracellular domain of the pIgR, also known as secretory component) in exocrine secretions to establish host-microbiota symbiosis and to mediate the protection of mucosal surfaces against pathogens (20, 21). The Fcα/μR, the Fc receptor for IgA and IgM, may play a role in systemic and mucosal immunity. It has been shown that none of the B cells, T cells, monocyte/macrophages, or NK cells in human blood samples expressed this receptor irrespective of age, ethnic origin or gender. Its expression is restricted to B cells from germinal center, follicular dendritic cells and tonsillar cells. Although, the exact function of the Fcα/μR is not fully clarified, it may play an important role in antigen presentation and B cell selection in the germinal center responses (22).

FcRs are divided into type I and type II on the basis of the conformational state of the Ig Fc domain that interacts with the receptor (1, 23). Type I Fc receptors interact with “open,” but not “closed” Ig Fc conformation (Figure 2). These receptors include...
**ITAM**

**Immunes complexes**

*FcγRIIA, hFcγRIIA*

\[\text{PLCγ, PI3K} \rightarrow \text{Ca}^{2+} \text{mobilization} \]

- **Cytokine/Chemokine production**
- **Oxidative burst**
- **ADCC**
- **Phagocytosis**

**ITIM**

**Co-igation**

*FcγRIIB, hFcγRIIA, BCR*

\[\text{PTEN, P3K} \rightarrow \text{DAG} \]

- **Negative regulation**

**ITIm**

**Monomeric Ig**

*FcγRIIA, LPS, TLR4, MD2*

\[\text{TRAF-6, IRAK1, IRAK1} \rightarrow \text{NFκB, Cytokine production} \]

**ACTIVATION**

**INHIBITION**

**INHIBITION**

**FIGURE 1** FcR signaling (e.g., FcγRII). (Left), the aggregation by an immune complex of FcR bearing ITAM motif (e.g., FcγRIIA) induces phosphorylation of the two ITAM tyrosine residues by Src kinases Lyn and Fyn responsible for recruitment and phosphorylation of Syk inducing cellular activation through PLCγ and PI3K signaling pathways. The PLCγ converts PI(4,5)P₂ into IP₃ and DAG. IP₃, a soluble inositol phosphate, leads to Ca²⁺ mobilization while DAG activate MAPK. PI3K converts PI(4,5)P₂ to PI(3,4,5)P₃ allowing recruitment of signal intermediates through their pleckstrin homology (PH) domain (Middle), co-ligation between an activating heterologous receptor (e.g., the BCR) and the inhibitory FcR (i.e., FcγRIIB) induces phosphorylation of the tyrosine present within the ITIM motif by Lyn (5), leading to the phosphorylation and recruitment of phosphatases (SHIP or SHP). The phosphatases PTEN and SHIP1/2 regulate cellular levels of PI(3,4,5)P₃ by hydrolyzing it to PI(4,5)P₂ and PI(3,4)P₂, respectively. These dephosphorylations inhibit cell proliferation. (Right), monovalent targeting of FcR bearing ITAM motif (e.g., FcγRIIA) induces the phosphorylation of the last tyrosine residue of the ITAM motif by Lyn responsible for transient recruitment of Syk followed by that of SHP-1 which abrogates the activation signal.

**FC RECEPTORS AND DISEASES**

**Gene Alleles**

Several single-nucleotide polymorphisms (SNPs) have been reported in the genes encoding activating FcγRs (FcγRIIA, FcγRIIIA, and FcγRIIB). In the gene encoding the inhibitory FcγRIIB, a SNP has been described which is associated with autoimmune diseases such as SLE and rheumatoid arthritis (RA) (34, 35). In addition to SNPs, copy-number variations (CNVs) of FcγR genes are associated with susceptibility to autoimmune disorders (34–40). Most polymorphisms concern the extracellular domains which bind to IgG, affecting the affinity between these receptors and IgG subclasses. However, no polymorphism and CNV have been clearly identified for FcγRI.

The most studied polymorphism is the one in the second Ig-like extracellular domain of the FcγRIIA that results in a point mutation of amino acid at position 131, coding for either arginine (R131) or histidine (H131). FcγRIIA-R131 binds less efficiently IgG2 than FcγRIIA-H131 (34). This Fcγr2a polymorphism has been described as a heritable risk factor for autoimmune and infectious diseases (41, 42). Moreover, genome-wide...
Figure 2 | Organization and conformational rearrangements of the IgE Fc. (left), IgE and the binding sites to FcεRI (green) and to CD23 (pink) [adapted from Pennington et al. (24)] (Middle and Right). Representation of the open and closed conformations, respectively, of the IgE Fc Cε3–4 domains, and the mutual allosteric inhibition by FcεRIα (green) and CD23 (pink).

Figure 3 | Human type I and II Fc receptors. Schematic representation of human Fc receptors at the cell membrane and their association or not with the Fcγ-chain dimer and the FcεRIβ chain, red circles represent the tyrosine residues. The FcγRIIB is anchored into the outer leaflet of the plasma membrane by a phosphatidylinositol-glycan (green circle).

Association studies (GWAS) revealed that FcγRIIA-H131 variant is associated with higher susceptibilities to develop Kawasaki disease and ulcerative colitis (43, 44). This variant is also associated with Guillain–Barré syndrome (45), supporting that immune complexes that include IgG2 auto-antibodies are involved in inflammatory responses. In contrast, the genotype homozygous for the FcγRIIA-R131 variant-encoding gene is associated with SLE, immune thrombocytopenic purpura (ITP) and IgA nephropathy (IgAN), revealing a complex and contrasted picture for the role of IgG2-containing immune complexes in autoimmune diseases (46–48). Regarding infectious diseases, neutrophils homozygous for the gene encoding the H131 variant show a higher capacity for IgG2-mediated phagocytosis than those homozygous for the gene encoding the R131 variant (41). In agreement, patients with the R encoding allele were found to have more severe cases of Severe Acute Respiratory Syndrome infection and were more susceptible to encapsulated microorganism infection, which was attributed to poor IgG2 binding to the R131 variant of FcγRIIA (41, 42). As mice do not express FcγRIIA homologs, transgenic mice expressing the FcγRIIB human gene encoding the R131 variant develop spontaneously autoimmune diseases such as pneumonitis, glomerulonephritis and RA (49, 50). Moreover, the fact that FcγRIIA-R131 expressed on the FcRγ-chain ITAM in mice similarly develop thrombocytopenia (51) and arthritis (11, 52) indicates that pro-autoimmune signals through FcγRIIA-R131 ITAM were sufficient to induce diseases. Biochemical analyses showed that two tyrosines of FcγRIIA ITAM motif were needed to induce inflammatory signals (53). Taken together, these animal models underline the critical involvement of Fcγ2a polymorphism in a number of diseases.

A polymorphism has been found in the inhibitory FcγRIIB-encoding gene that leads to a single I-to-T amino acid substitution in the transmembrane domain (residue 232)
Human monocytes expressing the FcγRIIB-T232 failed to inhibit heterologous receptors-mediated cell activation (55). The FcγRIIB-T232 polymorphism is associated with susceptibility to develop auto-immune diseases such as SLE (42, 54, 56). However, there are some discords concerning the SNPs in the promoter region of Fcgr2b, such as −386G and −120T (haplotype 2B.2), and −386C and −120A (haplotype 2B.4) variants. It has been shown that the 2B.4 SNP promoter haplotype upregulates the expression of FcγRIIB on neutrophils and monocytes that negatively correlates with lupus nephritis (46). This is in agreement with previous reports in mouse SLE-like models and suggests that FcγRIIB expression is protective in SLE (57). However, in striking contrast and in an apparent paradox, the same 2B.4 promoter haplotype was found by the same authors to correlate with SLE (46). This positive (SLE) vs. negative (lupus nephritis) paradoxical association of the 2B.4 promoter haplotype suggests multifaceted impacts of FcγRIIB in SLE that may depend on the affected cell types (e.g., monocytes vs. neutrophils). Alternatively, particular cell types expressing FcγRIIB could have aggravating or protective actions in SLE depending on which affected tissue these cells are recruited to, or on how these cells impact the systemic vs. local aspect of the disease. Thus, further investigation is necessary to elucidate the association of the promoter haplotype in disease development.

The FcγRIIA polymorphism is characterized by a point mutation in the codon for residue 158, encoding valine (V158) or phenylalanine (F158) in the Ig-like domain near the membrane (34–36). The FcγRIIA-V158 variant has a higher affinity for all human IgGs than the FcγRIIIA-F158 variant (40). The FcγRIIIA-F158 is associated with susceptibility to SLE, Crohn’s disease and Behçet’s disease (35, 36). Although studies have also explored the association between RA and the V or F 158 variant, their results have been contradictory and this question remains unsettled (58, 59).

Several FcαRI polymorphisms have been found, including two in the functional promoter region of the FcαRI encoding gene (−114T/C and +65T/C relative to the major transcription start site) (60). The incidence of the −114C/C polymorphism in patients with IgAN was significantly increased compared with other chronic kidney diseases (CKD) and healthy donors (HD) (15.6 vs. 4.0% in other CKD and vs. 2.4% in HD). This FcαRI polymorphism in the promoter region appears to be associated with susceptibility to IgAN, suggesting the importance of FcαRI expression in this disease. A third FcαRI polymorphism has been described in the coding region for FcαRI, which changes codon 248 from AGC to GGC leading to G248 instead of S248 in the cytoplasmic domain of the receptor (61). Interestingly, these two different alleles demonstrate significantly different FcαRI-mediated intracellular activating signaling. The proinflammatory FcαRI-G248 variant has been associated with SLE in two ethnic groups (61). However, this FcαRI polymorphism was not associated with other autoimmune diseases such as systemic sclerosis, RA or IgAN (62, 63). A fourth FcαRI polymorphism (A/G at nt 324) was also associated with aggressive periodontitis (64). Patients displaying the nt 324 A/A allele presented polymorphonuclear neutrophil dysfunctions with a decreased phagocytosis of periodontopathic bacteria (Porphyromonas gingivalis) as compared to patients expressing the nt 324 G/G (64).

Regarding the pIgR, it has been reported as a susceptibility gene for nasopharyngeal cancer (NPC) associated with Epstein-Barr virus (EBV) (65). This lead to a hypothesis that pIgR could be the nasopharyngeal epithelial receptor for EBV via IgA-EBV complex. Transcytosis failure due to missense C → T mutation on the PIGR1739 nucleotide (resulting in an A-to-V mutation on the endoproteolytic cleavage site of pIgR) could decrease the ability of pIgR to release IgA-EBV complexes, thus increasing susceptibility to develop NPC (65).

The high-affinity FcεRI is expressed by mast cells and basophils and plays an important role in allergic diseases. Several studies have identified two FcεRI polymorphisms associated with allergies. The −66T > C and/or the −315C > T are associated with atopic dermatitis, chronic urticaria, asthma, and high serum IgE levels (66–69). These polymorphisms were also associated with allergic inflammatory diseases such as atopy and nasal allergy (70, 71).

Table 1 summarizes most of described FcR alleles and their expression and functions in physiology and pathology (42–44, 46, 48, 60, 65, 66, 69, 72–83).

### Alterations in FcγR Expression

Several studies highlighted altered expression, structure and function of FcγRs in patients. Whereas, CD4+ T cells from healthy donors fail to express significant levels of FcγR, FcγRIIA is expressed in a subpopulation of CD4+ T cells in blood samples from HIV-1-positive patients and is highly enriched in inducible replication-competent proviruses suggestive of an FcγRIIA+ HIV reservoir (84). Yet, in other studies, FcγRIIA expression did not selectively enrich for HIV- or SIV-infected CD4+ T cells in peripheral blood or lymphoid tissue since resting FcγRIIA+ CD4+ T cells have <3% of the total HIV DNA amongst CD4+ T cells (85, 86). Taken together, whereas FcγRIIA expression in CD4+ T cells becomes a marker for HIV infection, the involvement of FcγRIIA+ CD4+ T cells in AIDS remains to be elucidated.

The inhibitory FcγRIIB, in contrast, is down-regulated in autoimmune diseases notably on both memory and plasma B lymphocytes of active SLE patients compared to those from healthy individuals (87). However, this down-regulation was not seen on myeloid-lineage cells. This was also observed in Hashimoto’s thyroiditis (88).

High level of FcγRIIIA expression on monocytes together with that of CD14 is associated with proinflammatory cytokine profiles and higher potency in antigen presentation allowing to define monocyte subsets with distinct phenotypes and functions (89).

For FcαRI, its expression is dysregulated in patients with AIDS, ankylosing spondylitis, alcoholic liver cirrhosis, Henoch-Schönlein purpura (HSP) and IgAN (90–93). Some of these studies have shown biochemical abnormalities revealing FcαRI altered protein mobility in SDS-PAGE suggesting altered glycosylation of this receptor (90). Interestingly, mutational studies of FcαRI indicate that the N58 residue of the receptor controls IgA-binding enhancement (94). In parallel,
abnormally glycosylated IgA1 molecules (hypogalactosylation and hyposialylation on the hinge region) observed in patients with IgAN and HSP is associated with the shedding of a soluble form of FcαRI (sFcαRI), which participates in the formation of circulating IgA1 complexes (95). These IgA1-sFcαRI complexes were decreased in serum of IgAN patients with severe and progressive disease as compared to non-progressive IgAN patients (96) suggesting a kidney deposition, and hence a possible nephrotoxic action, of such complexes which is further supported by studies in IgAN patients with recurrence of the disease after kidney transplantation (97). In this study, IgA1-sFcαRI complexes were decreased in the serum of patients with recurrent IgAN and sFcαRI was detected in the kidney mesangium only in patients with the recurrent disease. Direct evidence for a nephrotoxic role of IgA1-sFcαRI complexes were obtained in humanized animal models. These experimental studies were based on the fact that mouse do not have homologs of IgA1 and FcαRI. Humanized mice expressing human IgA1 and human FcαRI spontaneously develop mesangial deposits of IgA1-sFcαRI complexes (98). In the glomeruli, these complexes are captured by the transferrin receptor 1 (TfR1), which is upregulated on mesangial cells, through interaction with polymeric (p) IgA1 and FcαRI (98, 99). Although the mechanism of TfR1 upregulation remains poorly understood, the crosslinking enzyme transglutaminase 2 has been found to be overexpressed and associated with the receptor controlling mesangial IgA1 complex deposition and renal injury (98). Polymeric IgA1 induce TfR1 expression in vitro on mesangial cells. Polymeric IgA1-TfR1 interaction triggers activating signals through mTOR, PI3K and ERK pathways, and phosphorylated ERK is associated with disease progression (100). Interestingly enough, in physiology TfR1-IgA1 interaction plays a role in erythropoiesis (101). Progression of IgAN to end-stage renal disease may also involve FcR activation on tissue macrophages surrounding hypogalactosylated IgA1-mediated mesangial lesions. Indeed, FcαRIIα(Tg) mice, with an R-to-L substitution at position 209 in the transmembrane region of FcαRI, did not develop macrophage infiltration and proteinuria (102). This mutant receptor cannot associate with the ITAM-bearing FcγR signaling subunit (103). In agreement, only macrophages expressing wild-type FcαRI, but not those expressing FcαRIIα(R209L), were able to migrate to the kidney after adoptive transfer demonstrating that their chemotaxis depends

| Name                  | Subclass binding | Expression                                                                 | Functions                                       | Alleles                                                                                 | Link to diseases                                                                 |
|-----------------------|------------------|-----------------------------------------------------------------------------|-------------------------------------------------|------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| FcγRI (CD64)          | IgG 1/3/4        | Monocytes/Macrophages, Neutrophils/DCs/Mast cells                           | Activation                                     | –                                                                                       | –                                                                               |
| FcγRIIA (CD32a)       | H1311-IgG 1/2/3/4| Monocytes/Macrophages, Neutrophils/DCs/Basophils/Mast cells/Endothelial cells | Activation/inhibition                           | H1311/R131                                                                             | Kawasaki diseases (43), Ulcerative colitis (44), Childhood-onset ITP (71) | Lupus (45), IgAN (48), arthritis                                               |
| FcγRIIB (CD23b)       | IgG 1/2/3/4      | B cells/DCs/Mast cells/Basophils                                           | Inhibition                                     | Promoter–3SV or –120T232                                                                | Lupus (45)/lupus (42), Atopy (72)                                               |
| FcγRIIC (CD32c)       | IgG 1/2/3/4      | NK cells/ Monocytes/Macrophages /Neutrophils                                | Activation                                     | Q13/stop3                                                                              | Kawasaki disease (73)                                                          |
| FcγRIIA (CD16)        | V158^-IgG 1/2/3/4| NK cells/ Monocytes/Macrophages                                             | Activation/Inhibition                          | V158S/F158                                                                             | IgAN (48), arthritis severity (74), childhood chronic ITP (75)/Lupus (76), arthritis (58), Crohn's disease (77) |
| FcγRIIB (CD16b)       | IgG 1/3/4?       | Neutrophils/ Eosinophils/ Basrophils                                        | Activation                                     | Wegener's granulomatosis (78)                                                          |
| FcαRI (CD89)          | IgA1, IgA2, CRP  | Monocytes/Macrophages, Neutrophils/DCs/Kupffer cells (79)                  | Activation/inhibition                           | IgA nephropathy (63), AIDS, ankylosing spondylitis, alcoholic liver cirrhosis, Henoch-Schonlein purpura (HSP) (26) |
| FcμR                  | IgM              | B and T lymphocytes                                                         | Inhibition/?                                    | Chronic Lymphocytic Leukemia (CLL) (80), (81)                                           |
| FcαfμR                | IgM and IgA      | Germinal center B cell, Follicular dendritic cells                         | ?                                               | Atopic dermatitis, asthma and chronic urticaria (66–71)                                |
| FcRI                  | IgE              | Mast cells/DCs/Basophils                                                    | Activation                                     | 66T/31SC                                                                               | AIDS and B-CLL (82)                                                            |
| FcRII (CD23)          | IgE              | B cells and macrophages                                                     | Activation                                     | –                                                                                       |                                                                                 |
| FcRn                  | IgG 1/2/3/4      | Monocytes/Macrophages, Neutrophils/DCs/endothelial/ Syncytiotrophoblasts    | Recycling Transport uptake                      | VNTR1–5                                                                                |                                                                                 |
| PlgR                  | plgA             | Mucosal epithelium                                                          | Transcytosis                                    | 1739C to T                                                                              | Nasopharyngeal cancer and infection (65)                                        |
on the Fcγ subunit. Note that, FcαRI can be found associated and non-associated with Fcγ on the same cells (95). Since mouse IgA and human FcαRI interaction may be sufficient to induce receptor shedding leading to IgA deposits in the kidney, we hypothesized that both receptor types could cooperate to induce disease, the FcγIγ-less FcRγI allowing IgA deposits and the FcγI-associated FcRγI promoting inflammatory cell infiltration and disease progression (102).

For FcγRI (IGM receptor), deficiency in the receptor in mice revealed that this receptor plays a crucial role in B cell responses (27, 104). Mice deficient for FcμR are characterized by the increase in pre-immune serum IgM, dysregulation of humoral immune responses, disturbances in B cell populations, B cell proliferation alteration after BCR ligation, and autoantibody production (104, 105). Accordingly, in chronic lymphocytic leukemia (CLL), the membrane expression and the soluble form of FcμRI in serum were increased. The potential mechanism proposed for the up-regulation of FcμRI is that the antigen-independent self-ligation of BCR on CLL cells induces activation of Syk thus increasing the cell surface expression of FcμRI. Furthermore, the IgM antibodies produced by CLL cells that had differentiated into plasma cells, recognized soluble or lymphocyte membrane self-antigens. IgM/self-antigen immune complexes would then crosslink FcμRI and BCR favoring cell survival. An alternative splice variant of the soluble FcμRI is increased in CLL patients, but its biological function is unclear (105, 106).

For type II FcRs, an increased expression of FcγRII on monocytes in AIDS patients has been associated with the aberrant activated phenotype of these cells during the immunopathogenesis of AIDS. Interestingly, despite the known ability of IL-10 to downregulate monocyte FcγRI expression, in AIDS the IL-10-enriched environment is not associated with the suppression of FcγRII expression on monocytes (82) indicative of an impairment of this negative regulation in patients. In B-CLL also, patients strongly express FcγRII, which is associated with B cell activation and proliferation. Moreover, altered phosphorylation of FcγRII intracellular tail were reported in B-CLL B lymphocytes (107) further supporting an active role of FcγRII in this disease.

**TARGETING OF FC RECEPTORS AS THERAPEUTIC APPROACHES**

**Blocking/neutralizing Activating Receptor Antibodies**

Both murine models and studies in patients suggest a major role of the activating FcRs in initiating and propelling immune complex-mediated inflammatory reactions. For example, human FcγRIIA transgenic mice are hypersensitive to pathogenic antibodies and develop destructive arthritic syndromes. Ex vivo experimentation with circulating monocytes from RA patients suggest that FcγRIIA is responsible for the production of reactive oxygen species (11, 108). Anti-receptor monoclonal antibodies, intact antibodies and antibody fragments as well as a variety of small molecules have been designed to interact with the Ig-binding domains in activating FcRs. Some of these approaches have shown encouraging results when tested in vitro or in vivo for blocking immune complex-mediated cell effects and inflammation. Recently, we have demonstrated that dvalent targeting of FcγRIIA by anti-hFcγRII F(ab)2 fragments ameliorates RA-associated inflammation. This therapeutic effect was mediated by the induction of inhibitory ITAM (ITAMI) signaling through the activation of SHP-1. Moreover, treatment of inflammatory synovial cells from RA patients by F(ab)2 fragment of hFcγRIIIA-specific antibody inhibited production of reactive oxygen species associated with the induction of FcγRIIA-mediated ITAMI signaling. These data suggest that targeting of hFcγRIIIA by specific antibody such as clone IV.3 mAb could ameliorate RA-associated inflammation (11). Anti-FcγRI Fab and F(ab)2 fragments also have demonstrated efficiency on RA (109). Interestingly, in autoimmune blistering skin diseases that involve interaction between IgA autoantibodies and the neutrophil FcγRI, targeting FcγRI by blocking peptides or antibodies prevents neutrophil migration and tissue damage ex vivo (110, 111).

In allergy, treatment by anti-IgE antibodies has been considered a therapeutic option for a long time. The recombinant anti-IgE humanized monoclonal antibody-E25, named “omalizumab,” is now used in several clinical trials and shows efficacy against IgE-mediated allergic reactions (112, 113) through inhibition of IgE binding to FcεRI on the surface of mast cells and basophils (113).

The above-described upregulation of FcεRI expression in CLL cells is of significant clinical interest. It can be easily evaluated by flow cytometry on cells and, additionally, the levels of soluble FcεRI may correlate with disease progression. Thus, it may be used as a new biomarker for CLL (106). FcεRI is a good target also because it is involved in the pathogenesis of CLL and in the progression of the disease through support of leukemic cell survival (80). Hence, disrupting CLL survival signals might be achieved through FcεRI therapeutics coating. However, a large cohort of CLL patients will be required to validate these two applications (106).

**IVIG**

Intravenous immunoglobulins (IVIG) are harvested from the pooled plasma of 3,000 to 100,000 healthy donors. They consist of over 95% IgGs with a subclass distribution achieved through FcγRs in IVIG action. Another IVIG anti-inflammatory mechanism involves saturation of FcγRn, the IgG recycling receptor (118). FcγRn plays an important role in the maintenance...
of IgG half-life. Therefore, inhibition of autoantibody activity can be induced by the alteration of their interaction with FcRn, impairing their half-life and accelerating their clearing from the circulation. IVIG by competing with autoantibodies for FcRn binding could therefore facilitate their clearing.

A role for the inhibitory FcγRIIB has been proposed to be exclusive in IVIG action to explain their Fc dependent effect (118). This statement was based notably on studies showing a decreased anti-inflammatory effect of IVIG in FcγRIIB-deficient animals. In other studies, a role for FcγRIII in IVIG-mediated inhibition has been reported (119) although the mechanism of action was not clearly established. Recently, we reported that IVIG can control inflammatory responses by ITAMi signaling through FcγRIIA and FcγRIII (10, 11). These data are based on the in vitro targeting of FcγRIIA and FcγRIII by IVIG at the physiological concentration of IgG showing an inhibitory effect on endocytosis. This was confirmed by targeting FcγRIIA or FcγRIII with F(ab′)2 fragments of specific antibodies. These results were further supported in vivo in mice by targeting these receptors with IVIG or with specific antibodies and this inhibitory effect was abolished in receptor-deficient mice (10, 11). Therefore, IVIG could use a combination of non-exclusive mechanisms to promote protection against auto-immune diseases. Although IVIG is well tolerated, some patients develop immediate or delayed adverse effects depending on the time occurrence. The Flu-like symptoms such as fever, fatigue and nausea are the most frequent adverse effects. For the delayed adverse effects, the most frequent are thrombotic events, neurological disorders and renal failure. These delayed adverse effects are rare but dangerous (120). The majority of adverse effects are associated with high doses of immunoglobulins; thus, determining individual dosages to guarantee the efficacy of therapy and minimize adverse effects is an urgent goal.

Treatment with highly purified serum monomeric IgA (mIgA) decreases cell activation through FcαRI-Fcγ-mediated ITAMi signaling (109). Human mIgA or anti-FcαRI Fab fragments were used to prevent or treat collagen antibody-induced arthritis in FcαRI-transgenic mice. mIgA treatment decreased significantly leukocyte infiltration to the inflamed joints of mice, which was associated with SHP-1 phosphorylation at Y536 residue in joint tissue cells. Moreover, mIgA reversed the activating ITAM to ITAMi signature and the state of inflammation in the synovial fluid isolated from RA patients (109). Of note, protection was also achieved with human serum IgA (4). These findings open new avenues to develop the concept of IVIGA as a new treatment option for inflammatory and auto-immune diseases.

Other Future Strategies to Target FcR-Effectors to Treat Auto-Immune/Inflammatory Diseases

Targeting FcRn

Blocking FcRn-IgG interaction to decrease circulating IgG levels is one strategy to treat auto-immune disease (118). In the absence of interaction with FcRn, IgG would be degraded in lysosomes more quickly instead of being recycled back into circulation. One straightforward method would be to use recombinant soluble human FcRn to compete with membrane FcRn for IgG. Another approach to block IgG-FcRn binding would be through engineered “bait” IgG which occupy FcRn thus preventing binding of endogenous IgG. Such “bait” antibodies have been generated with a much higher affinity for FcRn at both acidic and neutral pH, thereby providing effective occupancy of FcRn, competing with, and resulting in, degradation of endogenous IgG. These antibodies are also called “Abdegs”; antibodies that enhance IgG degradation (125).

An FcRn-specific blocking mAb would also provide interference with FcRn-IgG interaction. One such mAb, 1G3, was examined in rat passive and active models of myasthenia gravis, a prototypical antibody-mediated auto-immune disease (126). Treatment by 1G3 mAb resulted in amelioration of disease symptoms in a dose-dependent manner together with greatly reduced levels of pathogenic antibody in the serum.
of Fyn may abolish inflammation during auto-immune and proinflammatory diseases. Taken together, inhibition of Fyn or of the molecules which are upstream or downstream this SFK reverses inflammation during auto-immune and inflammatory diseases and thus, could be a new therapeutic strategy to decrease the activating ITAM signaling in these diseases. Along these lines, inhibition of PI3K (a major player of the Fyn-PI3K-PKCα axis) prevents RA and lupus nephritis progression in mouse models (129). However, it should be mentioned that since Fyn is essential for activating ITAM signals (i.e., phagocytosis), the inhibition of this SFK may favor infections. Moreover, Fyn plays also other roles independently of FcRs. It has been shown that the absence of Fyn impaired multipolar-bipolar transition of newly generated neurons and neurite formation during the early phase of migration. Additionally, inhibition of Fyn decreased the branching number of the migrating cortical neurons (130). Another important hurdle is that Lyn and Fyn present a high homology and there are currently no selective inhibitory drugs. Therefore, Fyn does not appear as the best target to treat auto-immune and pro-inflammatory diseases. Identification of new targets which are downstream of Fyn and which are expressed specifically by immune cells involved in auto-immune diseases will permit development of new therapeutic strategies for autoimmune diseases that involve FcR.

CONCLUSION

Fc receptors may be responsible for diseases when dysregulated in spite of their physiologic protective function. Unraveling all aspects (expression, function, regulation) of FcR biology should help to define approaches to correct the first and to wielding the second to restore homeostasis thus representing new hopes for innovative anti-inflammatory strategies. Progress in these two aspects is currently well underway, already proposing new potent therapeutic tools. The future in this field is a promise of scientific excitement.

AUTHOR CONTRIBUTIONS

SB and RM wrote this review. MB has critically read the manuscript.

FUNDING

This work was funded by Inserm, by the Agence Nationale de la Recherche (ANR grants JC -17-CE17-0002-01, ANR PRC -18-CE14-0002-01), and also by LabEx Inflamex (ANR-11-IDEX-0005-02). RM was supported by “Equipe” program of the Fondation pour la recherche médicale (FRM).

REFERENCES

1. Pincetic A, Bournazos S, DiLillo DJ, Maamary J, Wang TT, Dahan R, et al. Type I and type II Fc receptors regulate innate and adaptive immunity. Nat Immunol. (2014) 15:707–16. doi: 10.1038/ni.2939
2. Bruhns P, Jonsson F. Mouse and human FcR effector functions. Immunol Rev. (2015) 268:25–51. doi: 10.1111/imr.12350
3. Kubagawa H, Kubagawa Y, Jones D, Nasti TH, Walter MR, Honjo K. The old but new IgM Fc receptor (FcμR). Carr Top Microbol Immunol. (2014) 382:3–28. doi: 10.1007/978-3-319-07911-0_1
4. Mkaddem SB, Murua A, Flament H, Titeca-Beauport D, Bounaix C, Danelli L, et al. Lyn and Fyn function as molecular switches that control immunoreceptors to direct homeostasis or inflammation. Nat Commun. (2017) 8:2126. doi: 10.1038/s41467-017-00924-0
5. Malbec O, Fong DC, Turner M, Tybulewicz VL, Cambier JC, Fridman WH, et al. Fc epsilon receptor I-associated lyn-dependent phosphorylation of Fc gamma receptor IIB during negative regulation of mast cell activation. J Immunol. (1998) 160:1647–58.
6. Bolland S, Ravetch JV. Inhibitory pathways triggered by ITIM-containing receptors. Adv Immunol. (1999) 72:149–77.
7. Pasquier B, Launay P, Kanamaru Y, Moura IC, Pfrirsch S, Ruffie C, et al. Identification of FcαRI-ITAM from activation to inhibitory signaling by both SHP-1 and SHIP-1 negative feedback pathways. Nat Immunol. (2004) 5:631–43. doi: 10.1038/nm1065
8. Kanamaru Y, Pfrirsch S, Aloulou M, Vrtovsnik F, Essig M, Loirat C, et al. Inhibitory ITAM signaling by Fc alpha RI-FcR gamma chain controls multiple activating responses and prevents renal inflammation. J Immunol. (2008) 180:2669–78. doi: 10.4049/jimmunol.180.4.2669
9. Aloulou M, Ben Mkaddem S, Biarnes-Pelicot M, Boussetta T, Souchet H, Rossato E, et al. IgG1 and IVlG induce inhibitory ITAM signaling through FcgammaRIII controlling inflammatory responses. Blood. (2012) 119:3084–96. doi: 10.1182/blood-2011-08-376046
10. Ben Mkaddem S, Hayem G, Jonsson F, Rossato E, Boedec E, Boussetta T, et al. Shifting FcgammaRIIA-ITAM from activation to inhibitory configuration ameliorates arthritis. J Clin Invest. (2014) 124:3945–59. doi: 10.1172/JCI74572
11. Bolland S, Ravetch JV. Of ITIMs, ITAMs, and ITAMis: revisiting immunoglobulin Fc receptor signaling. Immunol Rev. (2015) 268:66–73. doi: 10.1111/imr.12336
22. Kikuno K, Kang DW, Tahara K, Torii I, Kubagawa HM, Ho KJ, et al. Unusual biochemical features and follicular dendritic cell expression of human Fc alpha/mu receptor. Eur J Immunol. (2007) 37:5540–50. doi: 10.1002/eji.200737653

23. Ahmed AA, Giddens J, Pinetico A, Lominov JV, Ravetch JV, Wang LX, et al. Structural characterization of anti-inflammatory immunoglobulin G Fc proteins. J Mol Biol. (2014) 426:3166–3179. doi: 10.1016/j.jmb.2014.07.006

24. Pennington LE, Tarchevskaia S, Brigger D, Sathyamoorthy K, Graham NT, Nadeau KC, et al. Structural basis of ovalbumin therapy and ovalbumin-mediated IgE exchange. Nat Commun. (2016) 7:1610. doi: 10.1038/ncomms11610

25. Hogarth PM. Fc receptors are major mediators of antibody based inflammation in autoimmunity. Curr Opin Immunol. (2002) 14:798–802. doi: 10.1016/S0952-7915(02)00409-0

26. Monteiro RC, Van De Winkel JG. IgA Fc receptors. Curr Top Microbiol Immunol. (2003) 231:177–204. doi: 10.1007/978-1-282-141011

27. Kubaewa H, Oka S, Kubagawa Y, Torii I, Takayama E, Kang DW, et al. Identity of the elusive IgM Fc receptor (FcμR) in humans. J Exp Med. (2009) 206:2769–93. doi: 10.1084/jem.20091107

28. Shibuya A, Sakamoto N, Shintizu Y, Shibuya K, Osawa M, Horiyama T, et al. Specificity and affinity of human Fc gamma receptors and their polymorphic variants for human IgG subclasses. Clin Diagn Lab Immunol. (1993) 1:150–789–809.

29. Han MA, Gioglioti NM, Matangkasombut P, Vaquer C, Gostin A, Tussende E, Beaudoin L, et al. Secretory IgA induces tolerogenic dendritic cells through SIGN R1 dampening autoimmunity in mice. J Immunol. (2013) 191:2335–43. doi: 10.4049/jimmunol.1300864

30. Paul-Eugene N, Kolb JP, Abadie A, Gordon J, Delespesse G, Sarfati M, et al. CD23-mediated cell signaling in human B cells differs from signaling in cells of the monocytic lineage. J Immunol. (2015) 194:3730–37. doi: 10.1101/jimm.2015.08.005

31. Hargreaves CE, Rose-Zerilli MJ, Machado LR, Iriyama C, Hollox EJ, Cragg MS, et al. Fc gamma receptor polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility. Arthritis Rheum. (2002) 46:1242–54. doi: 10.1002/art.10257

32. Onouchi Y, Otsuki K, Burns JC, Shimizu C, Terai M, Hamada H, et al. Japanese kawasaki disease genome U. S. K. Consortium DG. A genome-wide association study identifies three new risk loci for Kawasaki disease. Nat Genet. (2012) 44:517–21. doi: 10.1038/ng.2220

33. Chan MA, Gigliotti NM, Matangkasombut P, Gauld SB, Cambier JC, et al. A genome-wide association study identifies three new susceptibility loci for ulcerative colitis in the Japanese population. Nat Genet. (2009) 41:1325–9. doi: 10.1038/ng.482

34. Asano K, Matsuhashi T, Umeno J, Hosono N, Takahashi A, Kawaguchi T, et al. A genome-wide association study identifies three new susceptibility loci for ulcerative colitis in the Japanese population. Nat Genet. (2009) 41:1325–9. doi: 10.1038/ng.482

35. van der Pol WL, van den Berg LH, Scheepers RH, van der Bom JG, van Doorn PA, van Koningsveld R, et al. IgG receptor IIa alleles determine susceptibility and severity of Guillain-Barre syndrome. Neurology. (2009) 53:1641–5. doi: 10.1212/WNL.53.5.1641

36. Li X, Gibson AW, Kimberly RP. Human FcR polymorphism and transgenic animal studies. Immunol Cell Biol. (2014) 92:423–34. doi: 10.1038/icb.2014.254

37. Reilly AF, Norris CF, Surya S, Bruchak FJ, Rappaport EF, Schwartz E, et al. Genetic diversity in human Fc receptor II for immunoglobulin G. Fc receptor IIa ligand-binding polymorphism. Clin Diag Lab Immunol. (1994) 1:150–789–809.

38. Fanciulli M, Norsworthy PJ, Petretto E, Dong R, Harper L, Kamesh L, et al. Secretory IgA induces tolerogenic dendritic cells through SIGN R1 dampening autoimmunity in mice. J Immunol. (2013) 191:2335–43. doi: 10.4049/jimmunol.1300864

39. Takai T. Roles of Fc receptors in autoimmunity. Nat Rev Immunol. (2002) 2:580–92. doi: 10.1038/nri856

40. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux P, et al. FcR polymorphic variants for human IgG subclasses. Curr Top Microbiol Immunol. (2014) 382:355–72. doi: 10.1007/978-3-319-17991-0_7

41. Sanders LA, Feldman RG, Voorhorst-Ogink MM, de Haas M, Rijkers GT, et al. Genetic diversity in human Fc receptor II for immunoglobulin G. Fc receptor IIa ligand-binding polymorphism. Clin Diag Lab Immunol. (1994) 1:150–789–809.

42. Kyogoku C, Dijstelbloem HM, Tsujiyama N, Hatta Y, Kato H, Yamaguchi A, et al. Fc gamma receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility. Arthritis Rheum. (2002) 46:1242–54. doi: 10.1002/art.10257
62. Broen JC, Coenen MJ, Rueda B, Witte T, Padyukov L, Klareskog L, et al. The functional polymorphism 844 A>G in FcalphaRI (CD89) does not contribute to systemic sclerosis or rheumatoid arthritis susceptibility. J Rheumatol. (2011) 38:446–9. doi: 10.3899/jrheum.100427.

63. Maillard N, Thubaudin L, Abadja F, Masson I, Garraud O, Berthoux F, et al. Single nucleotide polymorphism 844 A>G of FcαRI is not associated with IgA nephropathy in Caucasians. Nephrol Dial Transplant. (2012) 27:656–60. doi: 10.1093/ndt/gsf246.

64. Kaneko S, Kobayashi T, Yamamoto K, Jansen MD, van de Winkel JG, et al. Immunoglobulin immunoglobulin receptor polymorphisms and risk of nasopharyngeal cancer. BMC Genet. (2003) 4:3. doi: 10.1186/1471-2156-4-3.

65. Hanegi K, Kato Y, Koba T, Tanaka Y, Tomita S, et al. The genetic polymorphism of IgA Fc receptor in humans is associated with atopic dermatitis. J Dermatol Sci. (2006) 41:165–70. doi: 10.1016/j.jdermsci.2005.09.003.

66. Hasegawa M, Nishiya M, Akizawa Y, Mitsuishi K, Ito T, et al. A novel polymorphism in Fc epsilon RI alpha chain promoter affecting the transcription activity: possible relationship to allergic diseases. J Immunol. (2003) 171:1927–33. doi: 10.4049/jimmunol.171.4.1927.

67. Potaczek DP, Sanak M, Mastalerz L, Setkowicz M, Kaczor M, Nizankowska A, et al. Genetic polymorphism 844 A>G of the high-affinity IgE receptor beta chain and asthma. Allergy. (2006) 61:2123–30. doi: 10.1111/j.1398-9995.2006.01195.x.

68. Kim SH, Ye YM, Lee SK, Park HS. Genetic mechanism of aspirin-induced urticaria/angioedema. Curr Opin Allergy Clin Immunol. (2006) 6:266–70. doi: 10.1097/01.coi.0000235589.57182.d4.

69. Zhou J, Zhou Y, Lin LH, Wang J, Peng X, Li J, et al. Association of polymorphisms in the promoter region of FCR1A gene with atopic dermatitis, chronic urticaria, asthma, and serum immunoglobulin E levels in a Han Chinese population. Hum Immunol. (2012) 73:301–5. doi: 10.1016/j.humimm.2011.12.001.

70. Zhang X, Zhang W, Qiu D, Sandford A, Tan WC. The E237G polymorphism of the high-affinity IgE receptor beta chain and asthma. Ann Allergy Asthma Immunol. (2004) 93:499–503. doi: 10.1016/S1081-1206(04)61419-6.

71. Yang HJ, Zheng L, Zhang XF, Yang M, Huang X. Association of the MSA2 gene promoter C→T mutation with asthma risk: a meta-analysis. Clin Biochem. (2014) 47:605–11. doi: 10.1016/j.clinbiochem.2014.01.022.

72. Wu J, Lin R, Huang J, Guan W, Oetting WS, Siriramaoro P, et al. Functional Fc gamma receptor polymorphisms are associated with human allergy. PLoS ONE. (2014) 9:e89196. doi: 10.1371/journal.pone.0089196.

73. van der Heijden J, Breunis WB, Geisser I, de Boer M, van den Berg TK, Kuipers TPW. Phenotypic variation in IgG receptors by nonclassical FCGR2A alleles in IgA nephropathy. Am J Nephrol. (2013) 38:1318–24. doi: 10.1094/ajnl-100340.

74. Lee YH, Ji JD, Song GG. Associations between FCGR3A polymorphisms and risk of nasopharyngeal cancer. J Immunol. (2017) 199:2778–82. doi: 10.4049/jimmunol.175.8.2772.

75. Liu Y, Gong Y, Qu C, Zhang Y, You R, Yu N, et al. CD32b expression is down-regulated on double-negative memory B cells in patients with Hashimoto’s thyroiditis. Mol Cell Endocrinol. (2017) 441:1–7. doi: 10.1016/j.mce.2016.11.004.

76. Wong KL, Yeap WH, Tai JL, Ong SM, Dang TM, Wong SC. The three human monoocyte subsets: implications for health and disease. Immunol Res. (2012) 53:41–57. doi: 10.1007/s12026-012-8297-3.

77. Grossetete B, Launay P, Lefebvre A, Jungers P, Bach JF, Monteiro RC. Down-regulation of Fc alpha receptors on blood cells of IgA nephropathy patients: evidence for a negative regulatory role of serum IgA. Kidney Int. (1998) 53:1321–35.

78. Grossetete B, Viard JP, Lefebvre A, Bach JF, Monteiro RC. Impaired Fc alpha receptor expression is linked to increased immunoglobulin A levels and disease progression in HIV-1-infected patients. AIDS. (1995) 9:229–34. doi: 10.1097/00002030-199509030-00003.

79. Silvain C, Patry C, Launay P, Lefebvre A, Monteiro RC. Altered expression of monocyte IgA Fc receptors is associated with defective endocytosis in patients with alcoholic cirrhosis. Potential role for IFN-gamma. J Immunol. (1995) 155:1606–18.

80. Berthelot L, Jamin V, Viglietti D, Chemouny JM, Ayari H, Pierre M, et al. Value of biomarkers for predicting immunoglobulin A vasculitis nephritis outcome in an adult prospective cohort. Nephrol Dial Transplant. (2017) 32:1739–59. doi: 10.1093/ndt/gfw100.

81. Xue I, Zhao Q, Zha L, Zhang W. Deglycosylation of FcalphaRI at N58 increases its binding to IgA. Glycobiology. (2010) 20:905–15. doi: 10.1093/glycob/cwp048.

82. Monteiro RC. Recent advances in the physiopathology of IgA nephropathy. Nephrol Ther. (2018) 14(Suppl 1):S1–8. doi: 10.1016/j.nephro.2018.02.004.

83. Vuong MT, Hahn-Zoric M, Lundberg S, Gunnarsson I, van Kooten C, Wramner L, et al. Association of soluble CD89 levels with disease progression in IgA nephropathy. Kidney Int. (2010) 78:1281–7. doi: 10.1038/ki.2010.314.

84. Berthelot L, Robert T, Vuillet V, Tabary T, Bracconier A, Drane M, et al. Recurrent IgA nephropathy is predicted by altered glycosylated IgA, autoantibodies and soluble CD89 complexes. Kidney Int. (2015) 88:815–22. doi: 10.1038/ki.2015.158.
103. Cosmos, Monteleone M, Drago P, Parenti A, De Rosa V, et al. Identification of the receptor on mesangial cells as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy. J Exp Med. (2001) 194:417–25. doi: 10.1084/jem.194.4.4147

104. Tamouza H, Chemouny JM, Raskova Kafkova L, Berthelot L, Flamant M, Demion M, et al. The IgA1 immune complex-mediated activation of the MAPK/ERK kinase pathway in mesangial cells is associated with glomerular damage in IgA nephropathy. Kidney Int. (2012) 82:1284–96. doi: 10.1038/ki.2012.192

105. Coulon S, Dussiot M, Grapton D, McCollum TT, Wang PH, Callens C, et al. Polymeric IgA1 controls erythroblast proliferation and accelerates erythropoiesis recovery in anemia. Nat Med. (2011) 17:1456–65. doi: 10.1038/nm.2347

106. Kanamaru Y, Arcos-Fajardo M, Moura IC, Centelles MN, Malheiros DM, Collawn JF, Cooper MD, et al. Enhanced auto-antibody production and Mott cell formation in FcmuR-deficient autoimmune mice. Int Immunol. (2014) 26:659–72. doi: 10.1093/intimm/dxu070

107. Uchida R, Mori H, Hase K, Takatsu H, Kurosaki T, Tokuhisa T, et al. Critical role of the IgM Fc receptor in IgM homeostasis, B-cell survival, and humoral immune responses. Proc Natl Acad Sci USA. (2012) 109:E699–706. doi: 10.1073/pnas.120706109

108. Li F, Kubagawa Y, McCollum MK, Wilson L, Motohashi T, Wang PH, et al. Enhanced levels of both the membrane-bound and soluble forms of IgM Fc receptor (FcmuR) in patients with chronic lymphocytic leukemia. Blood. (2011) 118:4902–9. doi: 10.1182/blood-2011-04-350793

109. Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of Fc gamma receptors on dendritic cells. Nat Rev Immunol. (2007) 7:1116–28. doi: 10.1038/nri2120

110. Jin F, Balthasar JP. Mechanisms of intravenous immunoglobulin action and side effects. Curr Diabetes Rep. (2012) 12:240–7. doi: 10.1007/s11892-012-0267-0

111. Nimmerjahn F, Ravetch JV. Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis. Immunology. (2000) 100:277–85. doi: 10.1046/j.1365-2567.2000.00273.x

112. van Mirre E, van Royen A, Hack CE. IVIg-mediated amelioration of murine ITP via FcgammaRIIB is not necessarily independent of SHIP-1 and SHP-1 activity. Blood. (2004) 103:1973. doi: 10.1182/blood-2003-11-3933

113. Veri MC, Gorlatov S, Li H, Burke S, Johnson S, Stavenhagen J, et al. Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the activating Fc gamma-receptor IIA (CD32A): biochemical, biological and functional characterization. Immunology. (2007) 121:392–404. doi: 10.1111/j.1365-2567.2007.02588.x

114. Liu L, Garcia AM, Santoro H, Zhang Y, McDonnell K, Dumont J, et al. Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade. J Immunol. (2007) 178:5390–8. doi: 10.4049/jimmunol.178.8.5390

115. Zhang Z, Shen K, Lu W, Cole PA. The role of C-terminal tyrosine phosphorylation in the regulation of SHP-1 explored via expressed protein ligation. J Biol Chem. (2003) 278:6688–74. doi: 10.1074/jbc.M210028200

116. Jones ML, Craik JD, Gibbins JM, Poole AW. Regulation of SHP-1 tyrosine phosphatase in human platelets by serum phosphorylation at its C terminus. J Biol Chem. (2004) 279:40475–83. doi: 10.1074/jbc.M402970200

117. Camps M, Rucke T, Ji H, Ardissone V, Rintelen F, Shaw J, et al. Blockade of FcRIIgGammaj suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med. (2005) 11:939–43. doi: 10.1038/nm1284

118. Huang Y, Li G, An L, Fan Y, Cheng X, Li X, et al. Fyn regulates multipolar-bipolar transition and neurite morphogenesis of migrating neurons in the developing neocortex. Neuroscience. (2017) 352:39–51. doi: 10.1016/j.neuroscience.2017.03.032

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Ben Mkaddem, Benhamou and Monteiro. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Ben Mkaddem et al.